These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
487 related articles for article (PubMed ID: 29566416)
21. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370 [TBL] [Abstract][Full Text] [Related]
22. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. Dangas GD; Tijssen JGP; Wöhrle J; Søndergaard L; Gilard M; Möllmann H; Makkar RR; Herrmann HC; Giustino G; Baldus S; De Backer O; Guimarães AHC; Gullestad L; Kini A; von Lewinski D; Mack M; Moreno R; Schäfer U; Seeger J; Tchétché D; Thomitzek K; Valgimigli M; Vranckx P; Welsh RC; Wildgoose P; Volkl AA; Zazula A; van Amsterdam RGM; Mehran R; Windecker S; N Engl J Med; 2020 Jan; 382(2):120-129. PubMed ID: 31733180 [TBL] [Abstract][Full Text] [Related]
23. The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease. Camm AJ Thromb Haemost; 2018 May; 118(S 01):S2-S11. PubMed ID: 29566415 [TBL] [Abstract][Full Text] [Related]
24. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack. Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012 [TBL] [Abstract][Full Text] [Related]
25. Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. Healey JS; Gladstone DJ; Swaminathan B; Eckstein J; Mundl H; Epstein AE; Haeusler KG; Mikulik R; Kasner SE; Toni D; Arauz A; Ntaios G; Hankey GJ; Perera K; Pagola J; Shuaib A; Lutsep H; Yang X; Uchiyama S; Endres M; Coutts SB; Karlinski M; Czlonkowska A; Molina CA; Santo G; Berkowitz SD; Hart RG; Connolly SJ JAMA Neurol; 2019 Jul; 76(7):764-773. PubMed ID: 30958508 [TBL] [Abstract][Full Text] [Related]
26. [Rivaroxaban use in prevention of stroke in patients with non-valvular atrial fibrillation in clinical practice, results of observational studies and our experience]. Málek F Vnitr Lek; 2016; 62(10):814-819. PubMed ID: 27900868 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation. Barón-Esquivias G; Fernández-Avilés F; Atienza F; Pastor Pueyo P; Toro R; Sanmartín Fernández M Expert Rev Cardiovasc Ther; 2015 Apr; 13(4):341-53. PubMed ID: 25797900 [TBL] [Abstract][Full Text] [Related]
28. Rivaroxaban: an oral factor Xa inhibitor. Thomas TF; Ganetsky V; Spinler SA Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267 [TBL] [Abstract][Full Text] [Related]
29. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. Gibson CM; Mehran R; Bode C; Halperin J; Verheugt FW; Wildgoose P; Birmingham M; Ianus J; Burton P; van Eickels M; Korjian S; Daaboul Y; Lip GY; Cohen M; Husted S; Peterson ED; Fox KA N Engl J Med; 2016 Dec; 375(25):2423-2434. PubMed ID: 27959713 [TBL] [Abstract][Full Text] [Related]
30. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. Camm AJ; Fox KAA; Peterson E Europace; 2018 Jan; 20(1):1-11. PubMed ID: 29040518 [TBL] [Abstract][Full Text] [Related]
31. Challenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management. Sherwood MW; Vora AN Curr Cardiol Rep; 2018 Oct; 20(12):130. PubMed ID: 30311013 [TBL] [Abstract][Full Text] [Related]
32. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry. Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D; Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301 [TBL] [Abstract][Full Text] [Related]
33. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
35. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR Circulation; 2016 Jan; 133(4):352-60. PubMed ID: 26673560 [TBL] [Abstract][Full Text] [Related]
36. Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention. Gao F; Shen H; Wang ZJ; Yang SW; Liu XL; Zhou YJ Contemp Clin Trials; 2015 Jul; 43():129-32. PubMed ID: 26003433 [TBL] [Abstract][Full Text] [Related]
37. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1. Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424 [TBL] [Abstract][Full Text] [Related]
38. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795 [TBL] [Abstract][Full Text] [Related]
39. Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study. Yasuda S; Kaikita K; Ogawa H; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K Int J Cardiol; 2018 Aug; 265():108-112. PubMed ID: 29764706 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Vamos M; Cappato R; Marchlinski FE; Natale A; Hohnloser SH Europace; 2016 Dec; 18(12):1787-1794. PubMed ID: 26797248 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]